-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
-
Cosmetic Ingredient
- Water Treatment Chemical
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
Recently, through the official website of Jiahe Biotechnology, it was learned that its GB492 (IMSA101) Stimulator of interferon genes (STING) agonist has been officially accepted by the Center for Drug Evaluation (CDE) of the National Medical Products Administration.
The purpose of the clinical study for GB492 (IMSA101) application acceptance is to determine the phase II recommended dosing for GB492 monotherapy and combined recombinant anti-PD-1/L1 humanized monoclonal antibody (anti-PD-1/L1 monoclonal antibody) treatment Dose (RP2D), plan to enroll subjects with advanced malignancies who are refractory or unsuitable for standard treatment, including but not limited to melanoma, triple-negative breast cancer, liver cancer, head and neck cancer, renal cell carcinoma, gastroesophageal cancer And other cancer species.
It is understood that a number of previous studies have shown that interferon gene stimulating factor (STING) agonists can be used in combination with immune checkpoint inhibitors (ICI) as a new immunostimulatory therapy that can enhance the efficacy of cancer immunotherapy.
It is reported that Jiahe Biologics follow-up plans to jointly develop GB492 (IMSA101) and its anti-PD-1 antibody Gerolizumab (GB226) for the treatment of solid tumors.
GB492 (IMSA101) is an agonist of Stimulator of interferon genes (STING), which was granted an exclusive license agreement from ImmuneSensor Therapeutic by Jiahe Biologics in June 2020.
